Search details
1.
Personalised chemotherapy based on tumour marker decline in poor prognosis germ-cell tumours (GETUG 13): a phase 3, multicentre, randomised trial.
Lancet Oncol
; 15(13): 1442-1450, 2014 Dec.
Article
in English
| MEDLINE | ID: mdl-25456363
2.
Quality of Life and Cost-Effectiveness Assessment of Radioiodine Ablation Strategies in Patients With Thyroid Cancer: Results From the Randomized Phase III ESTIMABL Trial.
J Clin Oncol
; 33(26): 2885-92, 2015 Sep 10.
Article
in English
| MEDLINE | ID: mdl-26240230
Results
1 -
2
de 2
1
Next >
>>